Full text
Earnings transcript
Read the complete earnings call transcript.
CCJ
Cameco Corporation
$78.6
-0.33
(-0.42%)
| Exchange: | NYSE |
| Market Cap: | 34.233B |
| Shares Outstanding: | 313.17M |
Delayed data
About The Company
| Sector: | EnergyView sector performance | |||||
| Industry: | UraniumView industry performance | |||||
| CEO: | Timothy S. Gitzel | |||||
| Full Time Employees: | 3082 | |||||
| Address: |
| |||||
| Website: | https://www.cameco.com |
Cameco Corporation is a prominent global enterprise specializing in the production and distribution of uranium. Its operations are structured into two core divisions: Uranium and Fuel Services. The Uranium division manages the full upstream process, encompassing the exploration, extraction, and initial processing (milling) of uranium ore, as well as the procurement and sale of uranium concentrate. Conversely, the Fuel Services division focuses on the downstream transformation of uranium. This includes the refining, conversion, and fabrication of uranium concentrate into usable forms, alongside providing related conversion services. Furthermore, this segment is responsible for manufacturing specialized fuel bundles and reactor components specifically designed for CANDU reactors. Cameco provides its essential uranium products and associated fuel services to nuclear utility clients across major international markets, including the Americas, Europe, and Asia. The company was founded in 1987 and maintains its principal office in Saskatoon, Canada.
Click to read more…
Revenue Segmentation
CCJ full analysis
Welcome to MARKETSNAP’s SWOT analysis for Cameco Corporation, also known by its ticker CCJ. If you’re a long-term investor looking to dig into the potential of this major player in the uranium and nuclear energy space, you’re in the right place. Today, we’re breaking down the strengths, weaknesses, opportunities, and threats for Cameco, a company that’s been a cornerstone in the energy sector for years. Let’s dive into what makes this stock tick, explore some recent developments, and figure out…
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 2,587,758 | 3,135,772 | 3,479,095.453 |
| Gross Profit | 781,990 | 1,063,284 | 929,853.612 |
| EBITDA | 799,522 | 755,615 | 1,144,177.856 |
| Operating Income | 282,861 | 510,114 | 580,421.608 |
| Net Income | 360,847 | 171,853 | 589,096.533 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 9,934,057 | 9,907,007 | 10,292,887.134 |
| Total Liabilities | 3,839,748 | 3,542,674 | 3,395,134.931 |
| Total Stockholders Equity | 6,094,305 | 6,364,307 | 6,897,737.213 |
| Total Debt | 1,784,174 | 1,296,012 | 1,022,041.421 |
| Cash and Cash Equivalents | 566,809 | 600,462 | 1,113,951.462 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 688,136 | 905,288 | 1,354,685.120 |
| Capital Expenditure | -153,631 | -211,635 | -332,753.606 |
| Free Cash Flow | 534,505 | 693,653 | 1,021,931.514 |
| Net Income | 360,847 | 171,853 | 589,096.533 |
| Net Change in Cash | -576,865 | 33,653 | 541,415.067 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 4,558,458.592 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 4,839,614.913 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 4,695,274.754 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 2,956,741.454 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 3,163,837.821 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 3,057,520.353 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 2,127,738.397 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 2,299,892.663 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 2,211,513.490 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 410,057.165 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 435,348.645 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 422,364.494 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 5.080 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 5.280 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 4.880 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 5 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 4 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance and Growth: Cameco reported strong financial results for 2024, with revenue increasing to $3.14 billion from $2.59 billion in 2023, and free cash flow rising significantly to $693.65 million from $534.51 million. This reflects operational efficiency and a solid balance sheet, with a low debt-to-equity ratio of 0.153, indicating financial stability.
- Strong Market Position in Uranium Sector: As a leading uranium producer, Cameco benefits from its established presence in the nuclear energy market. The company’s performance across all segments, as highlighted in the 2024 earnings report, and its strategic focus on marketing, production, and financial discipline position it well to capture full-cycle value.
- Impressive Stock Performance: CCJ has shown exceptional long-term stock performance with a 5-year return of 447.52%, significantly outperforming its sector and industry averages (287.97% and 542.94%, respectively). Recent short-term gains (1-month: 29.63%, 3-month: 32.90%) further underscore investor confidence.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates CCJ intrinsic value between $59.35 – $68.07 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about CCJ valuation
Is Cameco Corporation (CCJ) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Cameco Corporation (CCJ) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is CCJ a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CCJ trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is CCJ’s P/E ratio?
You can see CCJ’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for CCJ?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is CCJ a good long-term investment?
Whether CCJ fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
CCJ
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.42
Trading Metrics:
| Open: | 78.43 | Previous Close: | 78.93 | |
| Day Low: | 76.92 | Day High: | 79.06 | |
| Year Low: | 76.92 | Year High: | 135.24 | |
| Price Avg 50: | 92.6 | Price Avg 200: | 105.1 | |
| Volume: | 3.103M | Average Volume: | 3.208M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
